This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Wellbutrin/SR
GlaxoSmithKline plc
Drug Names(s): Bupropion hydrochloride immediate release (IR)/sustained-release (SR)
Description: Biomedtracker has a separate entry for Wellbutrin XL.
Wellbutrin has three formulations: immediate release (three times daily), sustained released (SR, twice daily), and extended release (XL, once-daily).
Wellbutrin is an antidepressant that inhibits the reuptake of dopamine, norephinephrine, and to some extent serotonin. Its effect on dopamine is the most potent, but in actuality, it is a fairly weak reuptake blocker of all three of these, and its mechanism of action is not clear.
Deal Structure: All historical revenue for Wellbutrin is recorded under Wellbutrin/SR.
Wellbutrin/SR News
Pink Sheet In Brief: Wellbutrin SR
Pink Sheet In Brief: Glaxo's Wellbutrin SR
Pink Sheet In Brief: Glaxo Wellcome Wellbutrin SR
Additional information available to subscribers only:
- Targets
- Routes
- Catalysts
- Designations
- Events
Request a Free Demo Subscriber Login Search for another drug